ES2179862T3 - Utilizacion de rapamicina para el tratamiento de la anemia. - Google Patents

Utilizacion de rapamicina para el tratamiento de la anemia.

Info

Publication number
ES2179862T3
ES2179862T3 ES95308503T ES95308503T ES2179862T3 ES 2179862 T3 ES2179862 T3 ES 2179862T3 ES 95308503 T ES95308503 T ES 95308503T ES 95308503 T ES95308503 T ES 95308503T ES 2179862 T3 ES2179862 T3 ES 2179862T3
Authority
ES
Spain
Prior art keywords
rapamycin
anemia
treatment
mammal
intrabronchially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95308503T
Other languages
English (en)
Inventor
Jay Joseph Armstrong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2179862T3 publication Critical patent/ES2179862T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

EN ESTA INVENCION SE PRESENTA UN METODO PARA EL TRATAMIENTO DE LA ANEMIA INMUNORRELACIONADA DE UN MAMIFERO QUE CONSISTE EN ADMINISTRAR RAPAMICINA A DICHO MAMIFERO POR VIA ORAL, PARENTERAL, INTRAVASCULAR, INTRANASAL, INTRABROQUIAL, TRANSDERMICA, RECTAL.
ES95308503T 1994-12-13 1995-11-27 Utilizacion de rapamicina para el tratamiento de la anemia. Expired - Lifetime ES2179862T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/354,977 US5561138A (en) 1994-12-13 1994-12-13 Method of treating anemia

Publications (1)

Publication Number Publication Date
ES2179862T3 true ES2179862T3 (es) 2003-02-01

Family

ID=23395715

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95308503T Expired - Lifetime ES2179862T3 (es) 1994-12-13 1995-11-27 Utilizacion de rapamicina para el tratamiento de la anemia.

Country Status (12)

Country Link
US (1) US5561138A (es)
EP (1) EP0716857B1 (es)
JP (1) JPH08208661A (es)
KR (1) KR100423825B1 (es)
AT (1) ATE215822T1 (es)
CA (1) CA2164921A1 (es)
DE (1) DE69526311T2 (es)
DK (1) DK0716857T3 (es)
ES (1) ES2179862T3 (es)
HK (1) HK1010345A1 (es)
MX (1) MX9505187A (es)
PT (1) PT716857E (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
JP2004509898A (ja) 2000-09-19 2004-04-02 ワイス 水溶性ラパマイシンエステル
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
EP1419154B1 (en) 2001-08-22 2005-10-05 Wyeth Rapamycin 29-enols
EP1419153A1 (en) 2001-08-22 2004-05-19 Wyeth Rapamycin dialdehydes
BR0313024A (pt) 2002-07-30 2005-07-12 Wyeth Corp Formulações parenterais contendo um hidroxiéster de rapamicina
CN100415233C (zh) * 2002-09-17 2008-09-03 惠氏公司 口服制剂
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US20040258662A1 (en) * 2003-04-22 2004-12-23 Wyeth Antineoplastic agents
CA2566609C (en) 2004-05-13 2012-06-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CA2567883A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
CA2582374A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
AU2006315512B2 (en) 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
EP2431036B1 (en) 2006-09-13 2017-04-12 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
CN102231969A (zh) * 2008-10-03 2011-11-02 万能医药公司 大环内酯化合物及其使用方法
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
NZ611764A (en) 2008-11-13 2015-01-30 Gilead Calistoga Llc Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
EA019499B1 (ru) 2009-03-24 2014-04-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Производные атропоизомеров 2-пуринил-3-толилхиназолинона и способы применения
CN104997774A (zh) 2009-04-10 2015-10-28 齐海燕 新的抗衰老试剂及其鉴别方法
SG175259A1 (en) 2009-04-20 2011-11-28 Gilead Calistoga Llc Methods of treatment for solid tumors
WO2011011550A1 (en) 2009-07-21 2011-01-27 Calistoga Pharmaceuticals Inc. Treatment of liver disorders with pi3k inhibitors
US9364507B2 (en) * 2009-08-11 2016-06-14 Imagilin Technology, Llc Probiotic enhancement of steroid and immune suppressor activity in mammals with chronic diseases
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2013134288A1 (en) 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
EP2906214A1 (en) 2012-10-12 2015-08-19 The Board of Regents of The University of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
JP2017502021A (ja) 2013-12-20 2017-01-19 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤のためのプロセス方法
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
CA2952012A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
AU2021273065A1 (en) * 2020-05-15 2022-12-15 Celgene Corporation Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors
CN116459248B (zh) * 2023-04-27 2024-02-13 中国人民解放军陆军军医大学第二附属医院 雷帕霉素在制备治疗肿瘤相关性贫血的药物中的应用和药物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
DE69129459T2 (de) * 1990-08-10 1998-10-15 Anormed Inc Immunosuppressive zusammensetzungen
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB9302567D0 (en) * 1993-02-10 1993-03-24 Smithkline Beecham Plc Novel compound
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.

Also Published As

Publication number Publication date
DE69526311T2 (de) 2002-11-28
ATE215822T1 (de) 2002-04-15
MX9505187A (es) 1997-04-30
HK1010345A1 (en) 1999-06-17
KR100423825B1 (ko) 2004-06-26
CA2164921A1 (en) 1996-06-14
EP0716857A1 (en) 1996-06-19
EP0716857B1 (en) 2002-04-10
DK0716857T3 (da) 2002-08-05
KR960021019A (ko) 1996-07-18
DE69526311D1 (de) 2002-05-16
PT716857E (pt) 2002-08-30
US5561138A (en) 1996-10-01
JPH08208661A (ja) 1996-08-13

Similar Documents

Publication Publication Date Title
ES2179862T3 (es) Utilizacion de rapamicina para el tratamiento de la anemia.
KR930703001A (ko) 전신 홍반성낭창의 치료방법
NL300180I2 (nl) Toepasen van toxmoxetine voor het behandelen van de concentratiestoornis/hyperactiviteit aandoening.
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
PT1039887E (pt) Metodos para o tratamento de neuro e nefro disturbios e de toxicidades terapeuticas usando compostos de aminotiol
DK0789567T3 (da) En fremgangsmåde til behandling af vaskulære hovedpiner
FR2717546B1 (fr) Tendeur de courroie.
ES2059121T3 (es) Uso de agentes sensibilizantes de insulina para tratar la hipertension.
MX9205549A (es) Metodo para el tratamiento de vih.
BR0214020A (pt) Método para tratar fibrose cìstica
MX9205628A (es) Operaciones de oxidacion mejoradas para el tratamiento de desperdicios.
EA199800816A1 (ru) Способы лечения и профилактики интерстициального цистита
DE29906545U1 (de) Maschine zum Feinbearbeiten der Zahnflanken von verzahnten Werkstücken
DE69303305T2 (de) Mittel zur Behandlung chronischer Ermüdungserscheinungen
DK0571457T3 (da) Iloprost med virkning overfor cerebral malaria.
GB2310626B (en) Device for the finishing,particularly of crankshafts or camshafts
DE60129552D1 (de) E-selectin zur behandlung oder vorbeugung von schlaganfall
DE29821826U1 (de) Riemen für Gefäßbehandlungsmaschinen
BR9710901A (pt) M-todo para o tratamento da doen-a bipolar
DE60126766D1 (de) Zuführvorrichtung zum Zuführen von Stangen und Entfernen von Abfallstücken
ES1013369Y (es) Maquina elaboradora para el tratamiento de superficies de piezas de trabajo.
PT690712E (pt) Taxanos possuindo uma cadeia lateral substituida com piridilo
ES1030953Y (es) Maquina para el procesado de piezas de jamon.
FR2805755B1 (fr) Machine de traitement de skis a entrainement lateral
DE59710787D1 (de) Vorrichtung zum massfinishen von kurbelwellen oder dergleichen werkstücken